{"id":"str001-it-and-str001-er","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1375018","moleculeType":"Small molecule","molecularWeight":"280.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They work by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by binding to the GLP-1 receptor, which stimulates the release of insulin and inhibits the release of glucagon. This results in improved glycemic control and weight loss.","oneSentence":"STR001-IT and STR001-ER are glucagon-like peptide-1 (GLP-1) receptor agonists.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:37.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Type 2 diabetes with obesity"}]},"trialDetails":[{"nctId":"NCT03331627","phase":"PHASE3","title":"Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL","status":"COMPLETED","sponsor":"Strekin AG","startDate":"2018-02-24","conditions":"Acute Hearing Loss","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"STR001-IT and STR001-ER","genericName":"STR001-IT and STR001-ER","companyName":"Strekin AG","companyId":"strekin-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STR001-IT and STR001-ER are small molecule interventions being studied in a Phase III clinical trial for the treatment of Sudden Sensorineural Hearing Loss (SSHL), also known as Acute Hearing Loss. The trial, NCT03331627, is evaluating the safety and efficacy of these treatments in adults with SSHL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}